Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose

被引:25
作者
Moawad, Fouad J.
Hartzell, Joshua D.
Biega, Timothy J.
Lettieri, Christopher J.
机构
[1] Walter Reed Army Med Ctr, Dept Med, Washington, DC 20307 USA
[2] George Washington Univ, Med Ctr, Dept Neuroradiol, Washington, DC 20052 USA
[3] Pulm Crit Care & Sleep Med Serv, Washington, DC USA
[4] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA
关键词
posterior reversible encephalopathy syndrome; reversible posterior leukoencephalopathy syndrome; hypertensive encephalopathy; cortical blindness; ephedra;
D O I
10.1097/01.smj.0000215739.90211.3b
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Posterior reversible encephalopathy syndrome (PRES), also known as reversible posterior leukoencephalopathy syndrome (RPLS),. is most often associated with hypertensive emergencies and is characterized by seizures, mental status changes and visual disturbances. We report a case of a previously healthy young man who developed multiorgan failure and transient cortical blindness following ingestion of a performance-enhancing ephedra-based supplement. Neuroimaging findings confirmed the clinical suspicion of PRES. Radiographic abnormalities and neurologic dysfunction subsequently resolved with correction of his systolic blood pressure. This case emphasizes the need for prompt treatment and consideration of toxic ingestions in patients presenting with hypertension-related end-organ dysfunction.
引用
收藏
页码:511 / 514
页数:4
相关论文
共 14 条
  • [1] Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: Magnetic resonance imaging findings
    Bakshi, R
    Bates, VE
    Mechtler, LL
    Kinkel, PR
    Kinkel, WR
    [J]. EPILEPSIA, 1998, 39 (03) : 295 - 299
  • [2] The relative safety of ephedra compared with other herbal products
    Bent, S
    Tiedt, TN
    Odden, MC
    Shlipak, MG
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (06) : 468 - 471
  • [3] Casey SO, 2000, AM J NEURORADIOL, V21, P1199
  • [4] DALY PA, 1993, INT J OBESITY, V17, pS73
  • [5] Erythropoietin-associated hypertensive posterior leukoencephalopathy
    Delanty, N
    Vaughan, C
    Frucht, S
    Stubgen, P
    [J]. NEUROLOGY, 1997, 49 (03) : 686 - 689
  • [6] HYPERTENSIVE ENCEPHALOPATHY - MAGNETIC-RESONANCE IMAGING DEMONSTRATION OF REVERSIBLE CORTICAL AND WHITE MATTER LESIONS
    HAUSER, RA
    LACEY, M
    KNIGHT, MR
    [J]. ARCHIVES OF NEUROLOGY, 1988, 45 (10) : 1078 - 1083
  • [7] A reversible posterior leukoencephalopathy syndrome
    Hinchey, J
    Chaves, C
    Appignani, B
    Breen, J
    Pao, L
    Wang, A
    Pessin, MS
    Lamy, C
    Mas, JL
    Caplan, LR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) : 494 - 500
  • [8] Cyclosporine-related reversible posterior leukoencephalopathy: MRI
    Jarosz, JM
    Howlett, DC
    Cox, TCS
    Bingham, JB
    [J]. NEURORADIOLOGY, 1997, 39 (10) : 711 - 715
  • [9] Magnetic resonance imaging for the diagnosis of acute leukoencephalopathy in children treated with tacrolimus
    Lacaille, F
    Hertz-Pannier, L
    Nassogne, MC
    [J]. NEUROPEDIATRICS, 2004, 35 (02) : 130 - 133
  • [10] Safety concerns regarding ephedrine-type alkaloid-containing dietary supplements
    Miller, SC
    [J]. MILITARY MEDICINE, 2004, 169 (02) : 87 - 93